X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the license agreement, Nektar will utilize the Biolojic Design program TNFR2 receptor agonist, currently undergoing early-stage clinical trials for treating autoimmune diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undiclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Biolojic Design
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 24, 2024
Details:
Rezpeg (rezpegaldesleukin) is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance. It is being developed for Severe to Very Severe Alopecia Areata.
Lead Product(s): Rezpegaldesleukin
Therapeutic Area: Dermatology Product Name: Rezpeg
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
The net proceeds will be used for the development of NKTR-358 (rezpegaldesleukin), a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance, being developed for atopic dermatitis.
Lead Product(s): Rezpegaldesleukin
Therapeutic Area: Dermatology Product Name: NKTR-358
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: TCGX
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 04, 2024
Details:
The collaboration will evaluate Nektar's NKTR-255, a novel IL-15 receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy.
Lead Product(s): NKTR-255,C-TIL051
Therapeutic Area: Oncology Product Name: NKTR-255
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cellular Biomedicine Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
NKTR-358 (rezpegaldesleukin) T regulatory cell stimulator designed to target the interleukin-2 receptor complex to stimulate proliferation of regulatory T cells, which is investigated for the treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): Rezpegaldesleukin
Therapeutic Area: Dermatology Product Name: NKTR-358
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Under the agreement, Nektar regains the rights to Rezpeg (rezpegaldesleukin), a novel, first-in-class selective regulatory T-cell (Treg) therapy in clinical development. The company plans to move Rezpeg forward into Phase 2 clinical study in atopic dermatitis.
Lead Product(s): Rezpegaldesleukin
Therapeutic Area: Dermatology Product Name: Rezpeg
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 27, 2023
Details:
REZPEG (rezpegaldesleukin or NKTR-358) T regulatory cell stimulator designed to target the interleukin-2 receptor complex to stimulate proliferation of regulatory T cells. By activating these cells, REZPEG may act to bring the immune system back into balance.
Lead Product(s): Rezpegaldesleukin
Therapeutic Area: Immunology Product Name: NKTR-358
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response.
Lead Product(s): NKTR-255
Therapeutic Area: Oncology Product Name: NKTR-255
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
LY3471851/NKTR-358 (rezpegaldesleukin) is a novel, selective regulatory T-cell inducing IL-2 conjugate designed to target immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of regulatory T cells.
Lead Product(s): Rezpegaldesleukin
Therapeutic Area: Dermatology Product Name: NKTR-358
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response.
Lead Product(s): NKTR-255,Daratumumab
Therapeutic Area: Oncology Product Name: NKTR-255
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
